UTL-5g

UTL-5g (GBL-5g), an anti-inflammatory TNF-α inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors[1][2].

Product Specifications

CAS Number

[646530-37-2]

Product Name Alternative

GBL-5g

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/utl-5g.html

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=NOC(C)=C1)NC2=CC=C(Cl)C=C2Cl

Molecular Formula

C11H8Cl2N2O2

Molecular Weight

271.10

Precautions

H302, H315, H319, H335

References & Citations

[1]Stephen Brown, et al. UTL-5g Lowers Levels of TGF-β and TNF-α Elevated by Lung Irradiation|[2]Carruthers NJ, et al. Phosphoproteome and transcription factor activity profiling identify actions of the anti-inflammatory agent UTL-5g in LPS stimulated RAW 264.7 cells including disrupting actin remodeling and STAT-3 activation. Eur J Pharmacol. 2017;811:66-73.|[3]Shaw J, et al. The small-molecule TNF-α inhibitor, UTL-5g, delays deaths and increases survival rates for mice treated with high doses of cisplatin. Cancer Chemother Pharmacol. 2013;72 (3) :703-707.